⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
AXSM
VRTX
RLMD
VSTA
PRAX
NBIX
ALTO
LLY
JNJ
MRK
ABBV
BMY
REGN
BIIB
ANVS
ALEC
LEXX
COYA
NVO
IONQ
NVDA
AMD
INTC
GOOG
MSFT
AMZN
TSLA
AAPL
META
IBM
CRM
ADBE
NFLX
CMCSA
VZ
T
KO
PEP
MCD
DIS
BA
CAT
GE
XOM
CVX
JPM
BAC
WFC
GS
MS
V
MA
HD
WMT
COST
PG
PFE
MRNA
GILD
AMGN
NVS
TAK
EXAS
CRSP
EDIT
NTLA
INCY
ALKS
ACAD
AZN
TEVA
BHC
LULU
UBER
LYFT
SPCE
PLTR
SNOW
DDOG
CRWD
ZS
PANW
FTNT
NOW
ADSK
MCHP
NXPI
ON
QCOM
MU
WDC
SE
MELI
BABA
JD
PDD
NTES
BIDU
IQ
VIPS
NIO
XPEV
LI
RIVN
LCID
PLUG
FCEL
BE
SPWR
ENPH
SEDG
RUN
NEO
CLSK
CRBU
RXRX
DTIL
ADPT
CYTK
IMUX
MNKD
SRPT
BNTX
RVMD
ACRS
EXEL
FGEN
GNTX
HRMY
INSM
ITRM
KODK
LPCN
NCLH
OCGN
ORGO
PACB
PBYI
PEGA
PLRX
PRGS
PTON
PYPL
QGEN
QRVO
RDNT
REPL
ROKU
RYAAY
SAVA
SBAC
SCLX
SDRL
SEIC
SIRI
SMCI
SNPS
SOFI
SPOT
SSYS
STX
SWKS
SYK
TCOM
TEAM
TER
TGT
TMO
TMUS
TXN
UAL
ULTA
UPS
VRSK
WDAY
XEL
XYL
ZBRA
Global Microcarriers Market Poised for Strong Growth Through 2034, Fueled by Rising Cell Therapy, Vaccine Production and Biomanufacturing Demand
globenewswire.com
TMO
AMZN
AMGN
BMY
DHR
REGN
BNTX
MRK
COR
BDX
BIIB
GILD
VRTX
MDLZ
BKR
BIO
GEHC
MDT
ES
1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate ‘1ST-104’
globenewswire.com
BIIB
Boehringer Ingelheim launches PED Essentials, an online learning resource that gives patients a stronger voice
globenewswire.com
BIIB
Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
BNTX
ASO
IONS
BIIB
ALT
TEVA
TENX
UTHR
PFE
UNH
ABBV
GOSS
INSM
Viral Vector Collaboration and Licensing Deals 2016-2026 Report Examines 450+ Transactions, Deal Structures and Market Trends
globenewswire.com
AZN
BIIB
BMY
LLY
GILD
JNJ
NVS
PFE
SNY
TMO
VRTX
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
globenewswire.com
GILD
NVS
BMY
CRSP
BIO
ADBT
BIIB
JNJ
REGN
AMGN
CELC
ALLO
MBIO
AUTL
Leqembi® Pen subcutaneous formulation approved in Japan
prnewswire.com
BMY
BIIB
Leqembi® Pen subcutaneous formulation approved in Japan
prnewswire.com
BIIB
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
globenewswire.com
BIIB